International Clinical Trial: A Multicenter, Randomized, Double-blind, Parallel, Positive-controlled Phase III Clinical Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection (DUPIXENT(R)) in Participants with Moderate to Severe Atopic Dermatitis

Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132741) titled 'A Multicenter, Randomized, Double-blind, Parallel, Positive-controlled Phase III Clinical Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection (DUPIXENT(R)) in Participants with Moderate to Severe Atopic Dermatitis' on Sept. 17.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Dermatology Hospital of Southern Medical University (Guangdong Provincial Dermatology Hospital)

Condition: Moderate-to-severe atopic dermatitis

Intervention: Trial Group (IBI3027):Day 1 received a 600 mg loading dose subcutaneous injection (SC), followed by 300 mg each time, SC administration,...